KR20090077611A - Composition comprising orostachys japonicus extract for inhibiting obesity and for preventing or treating hyperlipidemia - Google Patents

Abstract

A composition for preventing or treating hyperlipidemia and suppressing obesity, which contains Orostachys japonicas extract is provided to reduce the weight of adipose tissue, total content of cholesterol, and low-density lipoprotein cholesterol and increase high-density lipid protein cholesterol. A composition for suppressing obesity comprises an Orostachys japonicas extract. A method for manufacturing the Orostachys japonicas extract comprises: a step of adding an Orostachys japonicas in water, alcohol or mixture solvent of water and alcohol; a step of filtering extract and compression-concentarating; a step of suspending the Orostachys japonicas extract in a distilled water and fractioning with chloroform three times; a step of solvent-fractioning with ethylacetate three times to obtain solvent fraction; a step of solvent-fractioning with n-butanol three time to obtain Orostachys japonicas butanol fraction; a step of concentrating to obtain water fraction; The composition is pharmaceutical composition or food composition.

Description

Composition comprising Orostachys japonicus extract for inhibiting obesity and for preventing or treating hyperlipidemia

The present invention relates to a composition for inhibiting obesity and preventing or treating hyperlipidemia, which comprises a Warsong extract.

There are many changes in eating habits due to recent economic growth and lifestyle changes. In particular, busy modern people are gaining weight and obesity due to high calorie diets such as fast food and low exercise.

Overweight means a body mass index (BMI, an obesity measure of body weight divided by the square of height) of 25 or more and less than 30. Obesity is applicable when the body mass index is 30 or more.

Two-thirds of American adults are overweight or obese, and overweight increases blood pressure and cholesterol levels, increasing the incidence of various adult diseases such as heart disease, and obesity increases the risk of heart disease, diabetes, arthritis and some cancers .

Overweight and obesity have contributed to increasing the incidence of various adult diseases such as arteriosclerosis, hypertension, hyperlipidemia or heart disease in children as well as adolescents.

As such, obesity affects all age groups, but the incidence of older adults is high. It is known that obesity was not so much in the East due to the vegetarian-oriented lifestyle, but in modern times, obesity gradually began to increase in Asians as the eating habits and the living environment changed due to the influence of western culture.

In addition, modern man has been reported that physical strength is reduced due to overwork, heavy drinking, stress, etc., about 30-40% have obesity, about 10% of them have severe or pathological obesity has been reported.

Obesity refers to a state in which fat is excessively accumulated in the body and a high proportion of fat in the body weight is classified into simple obesity and secondary obesity (symptomatic obesity).

The causes of simplicity obesity include overeating, lack of exercise, and decreased metabolism. The majority of cases that are clinically judged as obesity are simplicity obesity. If obesity manifests and the condition persists, it causes various health disorders.

Secondary obesity is obesity caused by any underlying disease, and may include endocrine obesity, hypothalamic obesity, hereditary obesity, or obesity due to drugs.

The main cause of obesity is overgrowth of fat cells, which is caused by a deficiency of a hormone called leptin, which is ordered and secreted by the brain. The deficiency of leptin hormone is reduced by overeating, weakening of metabolism in vivo due to aging, and animal cholesterol accumulated in the body, except when genetic deficiency occurs.

Obesity itself is the cause of various diseases such as hyperlipidemia, hypertension, cardiovascular disease, pseudotumor cerebri, sleep apnea, cancer, pulmonary hypertension, cholecystitis and osteoarthritis Or cause problems such as deterioration of activity. In addition, obesity may be caused by various diseases and may appear as a complication.

Hyperlipidemia is one of the most common diseases caused by obesity. Hyperlipidemia is an index of arteriosclerosis, which increases the synthesis of triglycerides and secretion of chylomicrons in the small intestine, increases the synthesis of triglycerides in the liver, and very low density lipoprotein-triglycerides (VLDL). ), Increased low density lipoprotein (LDL) -cholesterol synthesis and secretion, decreased synthesis of high density lipoprotein (HDL) -cholesterol, and reduced elimination of triglycerides in peripheral tissues due to decreased lipase activity. (Miller, NE 1978. The evidence for the antiatherogenicity of high density lipoprotein in man. Lipid ., 13 , 914--919.). Hyperlipidemia generally refers to the case where the blood cholesterol level is 240 mg / dl or more, and is recommended to be lowered below the normal level of 200 mg / dL. The causes of hyperlipidemia are heredity, alcohol consumption, high fat and high calorie meals, obesity, diabetes, liver dysfunction, thyroid dysfunction and nephrotic syndrome.

Drug therapy for the treatment of obesity currently being used include an appetite suppressant, digestive absorption inhibitors, obesity-inhibiting inhibitors or metabolic accelerators, these obesity drugs have a risk of causing side effects such as drug dependence. In addition, there is a problem in that resistance can be developed in a short period of time to a patient to be administered, so that it cannot be used continuously for a long time.

In addition, as a treatment method commonly used to treat hyperlipidemia, treatment through diet is preferred, but if it is not improved, bile acid-binding resins, nicotinic acid derivatives, and fibric acid induction Pharmaceuticals such as retention and probucol are used. Recently, the most widely used HMG CoA reducing agent inhibitor (3-hydroxyl-3-methylglutaryl-coenzyme A reductase inhibitor) and the like have been used as a therapeutic agent, but these drugs have not yet obtained a clinically satisfactory effect.

Therefore, many researchers are conducting research using herbal medicines to develop anti-obesity inhibitors and hyperlipidemia drugs that are not toxic to humans even after long-term use and have fewer side effects.

Orostachys japonicus is a perennial herbaceous plant with the dicotyledonous rosewood snails, also known as rock brush, and has been reported to have anticancer effects, antipyretic, geothermal, hepatitis, eczema, and burns in oriental medicine. In particular, liver cancer, breast cancer, pancreatic cancer, bone marrow cancer, esophageal cancer, uterine cancer, lymph gland cancer, stomach cancer, colon cancer, hypertension, hypotension, blood circulation, diabetes, stroke, arthritis, gastrointestinal disease, limb pain, hand and foot numbness, constipation, vomiting, various adult diseases It is known that there is effect. Soluble components reported so far are triterpenoids such as friedelin, epi-friedelanol, glutinone, and glutinol. Ryu; sterol-based materials such as β-sitosterol and campesterol; Fatty acid esters and flavonoids such as kaempferol and quercetin; And aromatic acids such as 4-hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, and gallic acid.

As mentioned above, various pharmacological effects are known for vortex, but the anti-obesity and antihyperlipidemic effects are not yet known and there is no research.

Therefore, the present inventors while studying the anti-obesity and anti-hyperlipidemic effect of the hawthorn extract, the administration of the hawsong extract in rats reared in a high-fat diet reduced food intake and weight, reduced the weight of fat tissue, serum And decreases lipid and total cholesterol in liver tissue, significantly decreases low-density lipoprotein cholesterol, significantly increases high-density lipoprotein cholesterol, significantly reduces arteriosclerosis risk index (AI), It was confirmed that the fat content was increased, and the present invention was completed.

The present invention is to provide a composition for inhibiting obesity and preventing or treating hyperlipidemia, including the pine fruit extract.

The present invention provides a composition for inhibiting obesity and preventing or treating hyperlipidemia, including a vortex extract.

Compositions according to the present invention include pharmaceutical compositions and food compositions.

Hereinafter, the present invention will be described in detail.

Wasong extract according to the present invention is prepared by extraction and separation in the following manner. First, vortex is added to water, alcohol or a mixed solvent of water and alcohol to extract reflux (3 times). The extract was filtered and concentrated under reduced pressure to obtain a vortex crude extract. The mixed solvent of water and alcohol may be selected from 10 to 100% methanol or 10 to 100% ethanol, preferably 10 to 100% methanol.

The crude feed extract is suspended in distilled water and solvent fractionated three times with chloroform to obtain a feed chloroform fraction. Then, the remaining aqueous layer was solvent fractionated three times with ethyl acetate to obtain a Warson ethyl acetate fraction, and the remaining aqueous layer was solvent fractionated three times with n-butanol to obtain a Warson butanol fraction. The remaining aqueous layer is concentrated to give a water fraction.

Whey extracts, in particular, Whey extract butanol fraction and Whey ethyl acetate fraction, reduced the food intake and body weight of the rats reared in a high fat diet, reduced the weight of adipose tissue, lipid and total cholesterol in serum and liver tissue Decreases, significantly reduces low density lipoprotein cholesterol, significantly increases high density lipoprotein cholesterol, significantly reduces arteriosclerosis risk index (AI), and increases fecal fat content. Therefore, the extracts according to the present invention can be used as medicines and health foods useful for inhibiting obesity and preventing or treating hyperlipidemia.

The composition of the present invention may contain one or more known active ingredients having an effect of inhibiting obesity and preventing or treating hyperlipidemia together with the vortex extract.

The composition of the present invention may be prepared by including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients for administration. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components, as necessary. And other conventional additives such as buffers and bacteriostatic agents can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

The composition of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is based on the weight, age, sex and health of the patient. The range varies depending on the diet, the time of administration, the method of administration, the rate of excretion and the severity of the disease. The daily dosage of the Wasong extract is about 1 to 1,000 mg / kg, preferably about 10 to 500 mg / kg, and more preferably, divided once to several times a day.

The composition of the present invention can be used alone or in combination with methods using surgery, hormonal therapy, drug treatment and biological response modifiers for the inhibition of obesity and the prevention or treatment of hyperlipidemia.

The composition of the present invention can be added to health food for the purpose of inhibiting obesity and improving hyperlipidemia. When using the walrus extract of the present invention as a food additive, the walrus extract can be added as it is or used with other foods or food ingredients, and can be suitably used according to a conventional method. The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment). In general, in the preparation of food or beverages, the extract of the present invention is added in an amount of up to 15% by weight, preferably up to 10% by weight based on the raw materials. However, in the case of long-term intake for health and hygiene or health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .

There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. Natural carbohydrates described above are glucose, monosaccharides such as fructose, malsaccharides, disaccharides such as sucrose, and polysaccharides such as dextrin, cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. In addition, the composition of the present invention may contain a pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the examples.

Example  One  : Preparation of Wasong Extract

3.6 kg of vortex was placed in a 5 L round bottom flask, and 3 L of methanol was added thereto, followed by extraction three times for 5 hours under reflux. The extract was filtered and concentrated under reduced pressure with a vacuum concentrator to give 268 g of Wasong methanol extract. The turmeric methanol extract was suspended in 2 L of distilled water, and then solvent fractioned with 0.8 L of chloroform to obtain a chloroform fraction (repeat three times). The chloroform fractions were collected and concentrated in vacuo to give 112 g of chloroform fractions. Then, the remaining aqueous layer was solvent fractionated with 0.8 L of ethyl acetate to obtain 17 g of ethyl acetate fraction (repeated three times). The remaining aqueous layer was solvent fractionated with 0.8 L of n-butanol to obtain 65 g of butanol fraction (repeat 3 times). The remaining aqueous layer was concentrated to give 96 g of water fractions.

Experimental Example  One  : Anti-obesity  And antihyperlipidemic effects

In order to determine the effect of the hawsong extract according to the present invention on the anti-obesity and anti-hyperlipidemic effect, the following experiment was performed.

1. Experimental Animal

The experimental animals were supplied with Sprague-Dawley male rats weighing 150 ± 10g from Hyochang Science, and were subjected to constant conditions (temperature: 20 ± 2 ℃, humidity: 40-60%, contrast: 12 hours day and night contrast cycles). 2 weeks under light / dark cycle). 24 hours before the start of the experiment only watered and fasted. At this time, the experimental animals were treated within a certain time (10:00 AM ~ 12:00 AM) in consideration of the daily variation of enzyme activity. The experimental animals were divided into seven groups and 6 animals were allocated to each group.

2. Induce hyperlipidemia and sample administration

After one week of adaptation of the experimental animals, one group was fed a normal diet as a normal group, and six experimental groups were freely fed a preparation sample containing wedges for 6 weeks to induce hyperlipidemia. The preparation sample is shown in Table 1.

The normal group and one high-fat diet group were administered 1 ml of physiological saline, respectively, and the five high-fat diet groups were Wahsong methanol extract, Wahsong chloroform fraction, Wahsong ethyl acetate fraction, Wahson butanol fraction and Wahsong prepared in Example 1 above. Water fractions were orally administered to experimental animals for 4 weeks using oral jonde at 100 mg / kg each using 4% Tween 80 dissolved in saline.

The statistical results of the experimental results were expressed as mean ± standard deviation, and statistical significance verification was shown by Duncan's multiple range test.

ingredient General diet (%) High fat diet (%) Casein 20.0 20.0 DL-Methionine 0.3 0.3 Corn starch 15.0 15.0 Sucrose 50.0 34.5 cellulose 5.0 5.0 Corn oil 5.0 - AIN-mineral mixture ^{1 )} 3.5 3.5 AIN-vitamin mixtures ^{2 )} 1.0 1.0 Choline bitartrate 0.2 0.2 Beef tallow - 20.5

※ 1) AIN-mineral mixture (g / kg dietary): dicalcium phosphate dibasic 500.0, NaCl 74.0, potassium citrate monohydrate 220.0, potassium sulfate 52.0, magnesium oxide ) 24.0, magnesium carbonate 3.5, ferric citrate 6.0, zinc carbonate 1.6, cupuric carbonate 0.3, potassium iodate 0.01, chromium potassium sulfate ) 0.55, sucrose, fine powder to 1,000.

2) AIN-vitamin mixture (g / kg diet): Thiamine HCl 0.6, Biotin 0.02, Riboflavin 0.6, Cyanocobalamine 0.001, Pyridoxine HCl 0.7, Retinyl acetate 0.8, Ticotinic acid 3.0, DL-tocopherol 3.8, Ca-pantothenate 1.6, 7-dehydrocholesterol 0.0025, folic acid 0.2, methionine 0.005, sucrose, fine powder to 1,000.

3. Measurement of food intake, weight change and adipose tissue weight

3-1. Measurement of food intake and weight change

Changes in food intake and body weight of rats fed a high-fat diet were measured weekly from the start of the experiment. Food intake and body weight change are shown in Table 2.

Sample volume (mg / kg) Food Intake (g / day) Weight gain (g / day) FER Normal - 29.3 ± 2.17 ^a 2.81 ± 0.43 ^a 0.096 ± 0.019 ^b It's a high-fat diet. - 22.4 ± 1.86 ^b 2.70 ± 0.38 ^ab 0.121 ± 0.013 ^a High Fat Diet + Wasong Methanol Extract 100 25.8 ± 2.05 ^ab 2.18 ± 0.29 ^b 0.084 ± 0.0010 ^c High Fat Diet + Wasong Butanol Fraction 100 16.8 ± 2.45 ^c 0.31 ± 0.009 ^c 0.018 ± 0.0015 ^c High fat diet group + Wasong ethyl acetate fraction 100 13.5 ± 1.67 ^c 0.25 ± 0.004 ^c 0.019 ± 0.0005 ^c High Fat Diet + Wasong Chloroform Fraction 100 22.9 ± 2.01 ^b 2.61 ± 0.40 ^ab 0.114 ± 0.0014 ^a High Fat Diet + Wasong Water Fraction 100 24.9 ± 1.83 ^b 2.43 ± 0.33 ^ab 0.098 ± 0.0013 ^b

※-FER (Food Efficiency Ratio) = weight gain / food intake

   -Values that follow the same letter are not significantly different (p <0.05).

As shown in Table 2, in the administration group of the Songsong extract, in particular the Wasong butanol fraction and Wasong ethyl acetate fraction according to the present invention was less food intake than other experimental groups, and showed a significant weight loss effect. In addition, the weight gain rate by food intake was also significantly lower.

3-2. Weight measurement of adipose tissue

The weight of adipose tissue in rats fed with a high fat diet was measured after incision of Retroperitoneal adipose tissue and Epididymal adipose tissue.

The weight of adipose tissue is shown in Table 3.

Sample volume (mg / kg) Abdominal cavity adipose tissue Epididymal adipose tissue Mg / g body weight Normal - 6.53 ± 0.40 ^c 7.32 ± 0.51 ^d It's a high-fat diet. - 11.30 ± 0.81 ^a 13.27 ± 0.48 ^a High Fat Diet + Wasong Methanol Extract 100 8.56 ± 0.39 ^b 10.26 ± 0.40 ^c High Fat Diet + Wasong Butanol Fraction 100 6.25 ± 0.29 ^cd 6.21 ± 0.13 ^e High fat diet group + Wasong ethyl acetate fraction 100 5.43 ± 0.41 ^d 5.83 ± 0.28 ^e High Fat Diet + Wasong Chloroform Fraction 100 10.92 ± 0.41 ^a 12.77 ± 0.39 ^a High Fat Diet + Wasong Water Fraction 100 10.53 ± 0.42 ^a 11.13 ± 0.45 ^b

※ There is no significant difference between the values following the same letter (p <0.05).

As shown in Table 3, the Warson butanol fraction and Warsong ethyl acetate fraction according to the present invention significantly reduced the weight of the celiac adipose tissue and epididymal adipose tissue.

4. Determination of Serum Lipid Content

Rats bred in a high-fat diet after the administration of the sample were intraperitoneally injected with sodium phenobarbital 200 mg / kg and anesthetized, and blood was collected from the abdominal aorta. The collected blood was centrifuged to use a supernatant.

4-1. Measurement of Serum Total Lipid Content

Serum total lipid was measured using a kit (AM 202-K, Asan) prepared by enzyme method of Richmond et al.

4-2. Determination of Serum Phospholipid Content

Serum phospholipid was measured using a kit (Iatron Chem. Co.) prepared by the enzyme method of Chen et al. In other words, the enzyme reagent (containing phospholipase 3.9U, choline oxidase 5.6U, peroxidase 3.6U, 4-aminoantipyrine 0.3252 mg) was dissolved in enzyme reagent solution [containing tris (hydroxy-methyl) -aminomethane 6.057 mg] in an ice-cold phase. 3.0 ml of the prepared enzyme solution was added to 20 µl, followed by incubation at 37 ° C. for 20 minutes to measure absorbance at a wavelength of 500 nm. The content was expressed in mg / dl according to the standard calibration curve.

4-3. Determination of Serum Triglyceride Content

Serum triglycerides were measured using a kit (AM 157S-K, Asan) prepared according to McGown et al. In other words, the enzyme reagent (containing lipoprotein lipase 10800U, glycerol kinase 5.4U, peroxidase 135000U, L-α-glycero phosphooxidase 160U) was dissolved in an enzyme reagent [N, N-bis (2-hydroxyethyl) -2-aminomethane sulfonic acid dissolved in 0.427 g /]], 3.0 ml of the enzyme solution prepared in 20 μl of the sample was added thereto, and the resultant was incubated at 37 ° C. for 10 minutes to measure absorbance at a wavelength of 550 nm. The blood content was expressed in mg / dl according to the standard calibration curve.

The results are shown in Table 4.

Sample volume (mg / kg) Total lipid (mg / ㎎) Phospholipids (mg / dl) Triglyceride (mg / ㎗) Normal - 200.4 ± 23.5 ^c 119.8 ± 15.8 ^b 67.9 ± 9.24 ^d It's a high-fat diet. - 383.8 ± 37.8 ^a 147.6 ± 16.4 ^a 154.5 ± 6.25 ^a High Fat Diet + Wasong Methanol Extract 100 376.7 ± 30.6 ^a 153.9 ± 9.5 ^a 140.7 ± 8.57 ^ab High Fat Diet + Wasong Butanol Fraction 100 341.8 ± 20.6 ^ab 131.7 ± 11.1 ^ab 123.5 ± 9.43 ^bc High fat diet group + Wasong ethyl acetate fraction 100 327.9 ± 23.9 ^b 121.5 ± 13.0 ^b 114.9 ± 6.23 ^c High Fat Diet + Wasong Chloroform Fraction 100 380.6 ± 20.4 ^a 151.7 ± 10.6 ^a 150.6 ± 14.7 ^a High Fat Diet + Wasong Water Fraction 100 385.6 ± 19.7 ^a 140.2 ± 12.1 ^ab 151.6 ± 11.6 ^a

※ There is no significant difference between the values following the same letter (p <0.05).

As shown in Table 4, the Warson butanol fraction and Warsong ethyl acetate fraction according to the present invention significantly reduced serum total lipid content, phospholipid content and triglyceride content.

5. Determination of Serum Cholesterol Content

5-1. Determination of Serum Total Cholesterol Content

Serum total cholesterol content was measured using a kit prepared by Richmon's enzyme method (AM 202-K, Asan). In other words, it contains enzyme reagents (potassium phosphate monobasic 13.6g / l, phenol 1.88g / l) in an ice-cooled bed with cholesterol esterase 20.5U / l, cholesterol oxidase 10.7U / l and sodium hydroxide 1.81g / l. After dissolving in), 3.0 ml of the prepared enzyme solution was added to 20 µl of the sample, followed by incubation at 37 ° C. for 5 minutes, and the absorbance at 500 nm was measured. The blood content was expressed in mg / dl according to the standard calibration curve.

5-2. Serum density Lipoprotein  Cholesterol Content Measurement

High-density lipoprotein cholesterol (HDL-C) content was measured using a kit (AM 203-K, Asan) prepared by the enzyme method such as Noma. That is, 0.2 ml of sedimentation reagent (containing dextran sulfate 0.1% and magnesium chloride 0.1M) was added to 20 µl of serum, and the mixture was mixed well, and left at room temperature for 10 minutes and centrifuged at 3000 rpm for 10 minutes. Next, 0.1 ml of the supernatant was mixed with 3.0 ml of enzyme solution, incubated at 37 ° C. for 5 minutes, and absorbance was measured at a wavelength of 500 nm. The content was expressed in mg / dl according to the standard calibration curve.

5-3. Serum low density Lipoprotein  Cholesterol Content Measurement

Low-density lipoprotein cholesterol (LDL-C) content was calculated by Equation 1 according to the method of Fridewald et al.

Low density lipoprotein cholesterol (LDL-C) = total cholesterol-[high density lipoprotein cholesterol (HDL-C) + (triglycerides / 5)]

The results are shown in Table 5.

Dose (mg / kg) Cholesterol (mg / ㎗) Arteriosclerosis Index (AI) Total cholesterol HDL LDL Normal 60.9 ± 4.63 ^c 44.5 ± 1.36 ^a 2.64 ± 0.33 ^c 0.37 ± 0.09 ^d It's a high-fat diet. 75.8 ± 3.22 ^a 37.4 ± 1.88 ^c 7.62 ± 0.85 ^a 1.03 ± 0.13 ^a High Fat Diet + Wasong Methanol Extract 100 74.6 ± 4.21 ^a 38.6 ± 3.10 ^bc 7.43 ± 0.41 ^a 0.93 ± 0.07 ^a High Fat Diet + Wasong Butanol Fraction 100 70.6 ± 2.43 ^ab 40.6 ± 2.98 ^abc 4.10 ± 0.29 ^b 0.74 ± 0.05 ^b High fat diet group + Wasong ethyl acetate fraction 100 68.1 ± 2.13 ^b 42.5 ± 2.23 ^ab 3.62 ± 0.27 ^b 0.60 ± 0.08 ^c High Fat Diet + Wasong Chloroform Fraction 100 75.0 ± 3.16 ^a 37.0 ± 3.19 ^c 6.98 ± 0.30 ^a 1.03 ± 0.06 ^a High Fat Diet + Wasong Water Fraction 100 73.4 ± 3.17 ^ab 36.5 ± 4.11 ^c 7.49 ± 0.47 ^a 1.01 ± 0.03 ^a

※ There is no significant difference between the values following the same letter (p <0.05).

As shown in Table 5, the Warson butanol fraction and Warsong ethyl acetate fraction according to the present invention significantly reduced serum total cholesterol and low density lipoprotein cholesterol, significantly increased high density lipoprotein cholesterol, and risk of atherosclerosis. The artherogenic index (AI) was also significantly reduced.

6. Fecal  Weight, and Feces  And In liver tissue  Fat content measurement

Fecals excreted in each experimental group for 24 hours were collected to measure the dry weight (dry weight). 2 g of fecal and liver tissues were taken to extract fat using the method of Folch and Stanley, which was precisely decanted to 25 ml with chloroform and used as analytical sample. Cholesterol content and neutral lipid content were measured using a kit, and 0.5% Triton X-100 was added to prevent turbidity.

The total lipid, triglyceride and cholesterol contents in liver tissue are shown in Table 6, and the dry weight of feces, triglyceride content and total cholesterol content in feces are shown in Table 7.

Total lipid, triglyceride and cholesterol content in liver tissue Sample volume (mg / kg) Total Lipids (mg / g) Triglyceride (mg / g) Cholesterol (mg / g) Normal - 12.7 ± 1.07 ^e 9.13 ± 0.72 ^d 2.50 ± 0.27 ^d It's a high-fat diet. - 28.9 ± 2.33 ^ab 19.6 ± 1.48 ^ab 5.27 ± 0.49 ^a High Fat Diet + Wasong Methanol Extract 100 31.7 ± 2.10 ^a 21.3 ± 2.47 ^a 4.86 ± 0.36 ^ab High Fat Diet + Wasong Butanol Fraction 100 25.8 ± 1.88 ^cd 17.6 ± 1.36 ^bc 4.63 ± 0.24 ^bc High fat diet group + Wasong ethyl acetate fraction 100 23.2 ± 1.45 ^d 16.2 ± 1.30 ^c 4.27 ± 0.31 ^c High Fat Diet + Wasong Chloroform Fraction 100 27.4 ± 1.33 ^bc 18.7 ± 1.96 ^abc 5.28 ± 0.27 ^a High Fat Diet + Wasong Water Fraction 100 29.0 ± 1.47 ^ab 19.8 ± 1.42 ^ab 5.19 ± 0.33 ^ab

※ There is no significant difference between the values following the same letter (p <0.05).

Dry weight of feces, triglyceride content and total cholesterol content in feces Sample volume (mg / kg) Dry weight (g / day) Triglyceride (mg / g) Total cholesterol (mg / g) Normal - 2.57 ± 0.18 ^a 18.3 ± 1.30 ^d 4.1 ± 0.80 ^d It's a high-fat diet. - 1.16 ± 0.19 ^b 23.2 ± 1.52 ^c 16.8 ± 2.36 ^c High Fat Diet + Wasong Methanol Extract 100 0.98 ± 0.14 ^bc 23.9 ± 1.53 ^c 20.7 ± 1.86 ^b High Fat Diet + Wasong Butanol Fraction 100 0.83 ± 0.13 ^c 40.7 ± 3.98 ^b 31.9 ± 2.25 ^a High fat diet group + Wasong ethyl acetate fraction 100 0.72 ± 0.18 ^c 48.9 ± 4.17 ^a 30.7 ± 1.43 ^a High Fat Diet + Wasong Chloroform Fraction 100 1.17 ± 0.17 ^b 25.3 ± 2.46 ^c 18.3 ± 2.11 ^bc High Fat Diet + Wasong Water Fraction 100 0.89 ± 0.16 ^bc 23.8 ± 2.11 ^c 17.3 ± 1.92 ^c

※ There is no significant difference between the values following the same letter (p <0.05).

As shown in Table 6, the Warson butanol fraction and Warsong ethyl acetate fraction according to the present invention significantly reduced the total lipid, triglyceride and cholesterol content in liver tissue.

In addition, as shown in Table 7, fat content in the feces of the group that was administered Waksong butanol fraction and Waksong ethyl acetate fraction according to the present invention was about 2 times higher than the high fat diet group. It is believed that this is because the Warson butanol fraction and the Warson ethyl acetate fraction according to the present invention reduce fat absorption in the intestine or increase excretion into the intestine.

Examples of preparations for the compositions of the present invention are illustrated below.

Formulation example  One  : Preparation of Pharmaceutical Formulations

1. Preparation of powder

Wasong Extract 2g

1g lactose

The above ingredients were mixed and filled in airtight cloth to prepare a powder.

2. Preparation of Tablets

Wasong Extract 100mg

Corn Starch 100mg

Lactose 100mg

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of Capsule

Wasong Extract 100mg

Corn Starch 100mg

Lactose 100mg

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

Formulation example  2  : Manufacture of food

1. Preparation of Cooking Seasonings

Wasong extract 20 to 95% by weight was prepared for health promotion cooking seasoning.

2. Preparation of Tomato Ketchup and Sauce

Health care tomato ketchup or sauce was prepared by adding 0.2 ~ 1.0% by weight of the quince extract to tomato ketchup or sauce.

3. Manufacturing of Flour Foods

0.5-5.0% by weight of pine nuts extract was added to the flour, and the mixture was used to prepare bread, cake, cookies, crackers, and noodles to prepare health-promoting foods.

4. Preparation of soups and gravy

0.1-5.0% by weight of the quince extract was added to soups and broth to prepare meat products for health promotion, soups and noodles of noodles.

5. Preparation of Ground Beef

Health weight ground beef was prepared by adding 10% by weight of the pine nuts extract to the ground beef.

6. Manufacture of Dairy Products

5-10% by weight of the hawthorn extract was added to milk, and the milk was used to prepare various dairy products such as butter and ice cream.

Formulation example  3  : Preparation of Beverages

1. Preparation of carbonated drinks

5-10% of sugar, 0.05-0.3% citric acid, 0.005-0.02% caramel, 0.1-1% of vitamin C are mixed, and 79-94% purified water is mixed to make syrup, and the syrup is 85-98 Sterilizing at 20 ℃ for 180 seconds, and then mixed with cooling water in a ratio of 1: 4, and then injected with 0.5 to 0.82% of carbon dioxide gas to prepare a carbonated beverage containing the Wahsong extract of the present invention.

2. Manufacture of health drinks

Homogeneous blending of subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%), and Wongsong extract, and sterilized them immediately Health drinks were prepared by packaging in small packaging containers such as plastic bottles.

3. Preparation of Vegetable Juice

5 g of the quince extract was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice for health promotion.

4. Preparation of Fruit Juice

1 g of the pine fruit extract was added to 1,000 ml of apple or grape juice to prepare fruit juice for health promotion.

Wahsong extract according to the present invention reduces the food intake and weight of rats reared in a high fat diet, reduce the weight of adipose tissue, reduce the lipid and total cholesterol in serum and liver tissue, and significantly lower lipoprotein cholesterol It can be useful for inhibiting obesity and preventing or treating hyperlipidemia by reducing the amount of fat, increasing high density lipoprotein cholesterol, significantly reducing arteriosclerosis risk index (AI), and increasing fecal fat content. .

Claims (11)

Obesity-inhibiting composition comprising a seungsong extract. The composition for inhibiting obesity according to claim 1, wherein the Wasong extract is a Wasong ethyl acetate fraction obtained by solvent fractionation of the Wasong methanol extract with chloroform and further solvent fractionation with ethyl acetate. The composition for inhibiting obesity according to claim 1, wherein the Waksong extract is a Wakson butanol fraction obtained by further fractionating the Wachson ethyl acetate fraction with n-butanol. The composition for inhibiting obesity according to any one of claims 1 to 3, wherein the composition is a pharmaceutical composition. The composition for inhibiting obesity according to any one of claims 1 to 3, wherein the composition is a food composition. Pharmaceutical composition for the prevention or treatment of hyperlipidemia comprising a hawsong extract. The pharmaceutical composition for preventing or treating hyperlipidemia according to claim 6, wherein the Wasong extract is a Wasong ethyl acetate fraction obtained by solvent fractionation of the Wasong methanol extract with chloroform and further solvent fractionation with ethyl acetate. 7. The pharmaceutical composition for preventing or treating hyperlipidemia according to claim 6, wherein the Wasong extract is a Wasong butanol fraction obtained by further fractionating the Wasong ethyl acetate fraction with n-butanol. A food composition useful for improving hyperlipidemia, comprising a quince extract. 10. The food composition of claim 9, wherein the Wasong extract is a Wasong ethyl acetate fraction obtained by solvent fractionation of the Wasong methanol extract with chloroform and further solvent fractionation with ethyl acetate. The food composition of claim 9, wherein the Waksong extract is a Wakson butanol fraction obtained by further fractionating the Wachson ethyl acetate fraction with n-butanol.